VacciMax® Vaccine Effectively Treats Melanoma in Mice
Author Information
Author(s): Mansour Marc, Pohajdak Bill, Kast W Martin, Fuentes-Ortega Antar, Korets-Smith Ella, Weir Genevieve M, Brown Robert G, Daftarian Pirouz
Primary Institution: ImmunoVaccine Technologies Inc., Halifax, NS, Canada
Hypothesis
Can a single vaccination of CTL/T helper peptides in VacciMax® effectively treat established B16-F10 melanoma tumors?
Conclusion
A single administration of VacciMax® can induce a strong immune response and successfully eliminate established melanoma tumors in mice.
Supporting Evidence
- The vaccine led to tumor eradication in all treated mice.
- Control vaccines without liposomes resulted in only 20% tumor-free mice.
- The study demonstrated that targeting multiple antigens simultaneously enhances immune response.
Takeaway
The study shows that a special vaccine can help mice fight off skin cancer by making their immune system stronger.
Methodology
C57BL/6 mice with B16-F10 melanoma were vaccinated with a mixture of peptides and monitored for tumor growth and immune response.
Potential Biases
Potential bias due to authors' affiliations with ImmunoVaccine Technologies Inc.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
C57BL/6 female mice, 6–8 weeks of age.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website